Neuland Laboratories Ltd (NEULANDLAB)
₹19,700.00
Mkt cap
₹25,275 Cr
P/E ratio
50.80
P/B
13.48
Div yield
0.17%
ROE
21.20%
ROCE
26.50%
EPS (TTM)
₹387.80
Book value
₹1,461
52W range
11,500–24,225
Sector
Healthcare
Price history
Previous close
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. [1]
NSE NEULANDLABBSE 524558
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−18.68% from high₹19,700
₹11,500+71.30% from low₹24,225
Current
₹19,700.00
Prev close
₹19,280.00
Day
+2.18%
Price performance
1D
+1.66%
1W
+3.90%
1M
−8.30%
3M
+2.07%
6M
+33.73%
1Y
+21.00%
YTD
+28.96%
Financials
Revenue, profit & margin
P/E ratio
50.8×
NEULANDLAB is 48% above the sector median of 34.4×
NEULANDLAB50.8×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 | |
| Expenses | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 | |
| Operating Profit | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 | |
| OPM % | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% | |
| Other Income | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 | |
| Interest | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 | |
| Depreciation | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 | |
| Profit before tax | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 | |
| Tax % | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% | |
| Net Profit | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 | |
| EPS in Rs | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
3 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.42% · closed higher next day 21 of last 63
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 8 Feb '24◦ | 10 May '24◦ | 1 Aug '24◦ | 6 Nov '24 | 10 Feb '25◦ | 15 May '25 | 31 Jul '25◦ | 7 Nov '25◦ | 9 Feb '26◦ | 12 May '26◦ | 5 Aug '26◦ |
| Earnings day | +7.02% | +3.71% | −15.11% | +18.08% | −10.68% | −6.85% | −6.77% | −1.99% | +1.55% | −2.79% | −2.98% | +7.95% |
| +1 day | +14.02% | −1.14% | −13.56% | +16.84% | −13.11% | −7.00% | −5.41% | −1.49% | −3.61% | −5.04% | −1.90% | +14.53% |
| +5 days | +14.86% | +9.53% | −12.81% | +22.76% | −7.52% | −24.85% | −5.93% | −1.37% | −2.70% | −1.59% | −2.23% | +16.29% |
| +15 days | +16.41% | +11.35% | −14.36% | +26.85% | +5.37% | −19.31% | +9.87% | +1.85% | −7.01% | −8.02% | −0.84% | +17.74% |
| +30 days | +10.88% | −1.11% | +2.83% | +36.47% | −12.40% | −17.75% | +2.20% | +22.14% | −11.74% | −12.92% | +5.63% | +14.45% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 34 Per Share | 34.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Sep 202632.26%Promoter
Promoters32.26%0.36
FIIs21.93%0.85
DIIs16.25%0.27
Public29.55%0.24
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Neuland Labs. | ₹19,700.00 | 50.78 | 25,275 | 0.17% | 148 | +962.37% | 642 | +119.16% | 26.47% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports15
Concall transcripts77
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Credit ratings6
Announcements5
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 29 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 24 OctBoard Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026 22 Oct - Board meets November 3, 2026 to approve Q2 and half-year FY2026 unaudited results.Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 14 Oct - USFDA issued EIR and closed Unit 3 inspection conducted August 10-14, 2026.